This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Pharma/Biotech GTN Summit
November 18-20, 2024
W Philadelphia HotelPhiladelphia, PA

Chris Sloan
Director, Market Access Strategy at Blueprint Medicines


Chris is a Director of Market Access Strategy at Blueprint Medicines and has 10+ years’ experience in consulting and life sciences industries. He specializes in the intersections of US market access, drug pricing, and policy reforms. His economic analyses of key policy proposals and issues, including drug pricing and the repeal and replace efforts around the ACA, have been featured in a wide range of publications, including the Wall Street Journal, the New York Times, the Washington Post, and Politico. He holds an MS in Healthcare Decision Analysis from the University of Southern California and a BBA in Economics from the College of William & Mary.

Agenda Sessions

  • Keynote Panel Discussion: Navigating the evolving regulatory and financial landscape – Key considerations and recommendations for IRA, the AMP cap removal and future drug policy proposals